What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Psychiatry
- Disease
Mondher Toumi mainly investigates Psychiatry, Cohort study, Mental health, Schizophrenia and Quality of life. His Schizophrenia study in the realm of Psychiatry interacts with subjects such as Social environment. His work in Cohort study covers topics such as Cohort which are related to areas like Atypical antipsychotic.
His Mental health research includes themes of Proportional hazards model, Epidemiology, Depression and Chronic condition. Mondher Toumi interconnects Cochrane Library and Disease, Disease burden in the investigation of issues within Schizophrenia. His studies in Quality of life integrate themes in fields like Psychosis and Cross-cultural studies.
His most cited work include:
- Rates and correlates of employment in people with schizophrenia in the UK, France and Germany (248 citations)
- Relapse in schizophrenia: costs, clinical outcomes and quality of life (201 citations)
- Humanistic burden in schizophrenia: A literature review (120 citations)
What are the main themes of his work throughout his whole career to date?
Mondher Toumi spends much of his time researching Psychiatry, Schizophrenia, Schizophrenia, Clinical psychology and Health care. His Psychiatry research is multidisciplinary, incorporating elements of Quality of life, Cohort study and Cohort. His Health care research is mostly focused on the topic Health policy.
He most often published in these fields:
- Psychiatry (27.70%)
- Schizophrenia (8.71%)
- Schizophrenia (8.71%)
What were the highlights of his more recent work (between 2017-2021)?
- Orphan drug (6.60%)
- Family medicine (5.80%)
- Drug (3.17%)
In recent papers he was focusing on the following fields of study:
His main research concerns Orphan drug, Family medicine, Drug, Bioinformatics and Procurement. His study in Orphan drug is interdisciplinary in nature, drawing from both Economic growth, Disease area, Socioeconomics and Monetary economics. Mondher Toumi applies his multidisciplinary studies on Family medicine and Nice in his research.
His research brings together the fields of Finance and Drug. Mondher Toumi does research in Bioinformatics, focusing on Clinical trial specifically. In his research, he undertakes multidisciplinary study on Procurement and Public administration.
Between 2017 and 2021, his most popular works were:
- Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update. (25 citations)
- Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. (15 citations)
- Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review (10 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Statistics
- Disease
His primary scientific interests are in Systematic review, Family medicine, Risk analysis, Internal medicine and Atrial fibrillation. His studies deal with areas such as Physical therapy, Randomized controlled trial, Overactive bladder and Epidemiology as well as Systematic review. His work focuses on many connections between Family medicine and other disciplines, such as Pulmonologists, that overlap with his field of interest in Health care.
His Health care research is multidisciplinary, incorporating perspectives in One Health, Informed consent, Palliative care and Weakness. His study in the field of Meta-analysis and Vitamin K antagonist also crosses realms of Wet age-related macular degeneration and Anti vegf. The concepts of his Apixaban study are interwoven with issues in Lower risk, Cochrane Library, Myocardial infarction and Intensive care medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
